exact sciences #exasirday: our leaders

T H E E X A C T L E A D E R S

2

Exact Sciences is fueled by passion, innovation and Madison’s entrepreneurial spirit.

People join Exact Sciences to generate real change. And together we have, pairing creativity with rigorous science to produce Cologuard®, then proving its performance in one of the largest clinical trials of its kind.

We began with strong science and successfully applied it to the development of a test that is changing human behavior—how people are screened for today’s second deadliest cancer. We built a flexible lab and customer care center that can be scaled to take on other cancers through early detection. And we did it all because of the remarkable people of Exact Sciences.

There is a new model for success.

Meet the leadership team that is making it happen.

Joined Exact Sciences: 2009

Key Responsibility: Oversee the company’s strategy in cooperation with the board and investors, create and foster a culture of collaboration and innovation, build a strong leadership team and ensure company resources are properly allocated to create the most value

Previous Employment: chief executive officer, president, Third Wave Technologies; intellectual property counsel, GE Healthcare; chief operating officer, venture-backed technology companies; intellectual property litigator, McDermott Will & Emory; partner, Pattishall, McAuliffe, Newbury, Hilliard and Geraldson

Education: JD, University of Michigan Law School; BS, Michigan State University

What excites me most about working at Exact Sciences? Solving hard problems with exceptional people. It’s incredibly energizing to know that our collective ability and experience is making a real difference in the early detection of cancer, a space in which few companies have been able to carve out a leadership position. I’m just as excited that we’re putting our skills and know-how to work bringing other products to market where we can make a similar difference.

The mission we’ve outlined and the challenges in front of us put Exact Sciences in a unique leadership position to help win the war on cancer through early detection.

KEVIN C O N R O YC H A I R M A N O F T H E B O A R D , C H I E F E X E C U T I V E O F F I C E R A N D P R E S I D E N T

4


Key Responsibility: Drive commercial execution while achieving excellent service in operations and the lab

Previous Employment: chief financial officer, Third Wave Technologies; director of corporate strategy & new ventures, Nalco; brand management, Kraft Foods

Education: MBA, Kellogg Graduate School of Management, Northwestern University; BA, University of Chicago

We are working to establish Cologuard as a key frontline defense to curb the incidence and mortality of colorectal cancer. But for Exact Sciences, the challenge of taking on colon cancer isn’t enough. Our unique skillset used to develop and commercialize tests that detect cancer early can be leveraged to fight lung, pancreatic and esophageal cancers as well.

All of us are excited that these efforts are making a real difference in the lives of people across the country. We’re off to a strong start and look forward to achieving great things in the future.

MANEESH A R O R AS E N I O R V I C E P R E S I D E N T A N D C H I E F O P E R A T I N G O F F I C E R


Key Responsibility: Oversee the company’s research and product development organization

Previous Employment: senior vice president of research and development, Nanogen, Inc.; vice president research and development, Gen-Probe Inc.; co-founder and vice president of product development, Matritech, Inc.; Ciba Corning Diagnostics Corp.

Education: PhD, BA (Honors), University of Manchester, England

All of us at Exact Sciences take great pride in what we do. It’s that pride in our work that has enabled all the accomplishments that led to the launch of Cologuard and is fueling the future of the company. I am proud to have been a member of the Exact Sciences team during the years that drove the development and FDA approval of Cologuard. I’m confident that even bigger things lie ahead.

GRAHAM L I D G A R DC H I E F S C I E N C E O F F I C E R

6


Key Responsibility: Serve as chief legal officer

Previous Employment: managing partner, K&L Gates; general counsel, Blue Rhino Corporation; associate general counsel, GE Medical Systems; partner, Smith Anderson

Education: JD, Columbia Law School; BS, University of North Carolina, Chapel Hill

Industry Organizations: North Carolina Bar Association; secretary and treasurer, Business Law Council

t’s exciting to be part of an organization that is playing a major role in the eradication of colorectal cancer. And I should know: I took the test shortly after turning 50 and had a positive result. A subsequent colonoscopy confirmed that I had precancerous lesions. Cologuard made it easy for me to be screened, and as it turned out, I didn’t have time to procrastinate!

SCOTT C O W A R DS E N I O R V I C E P R E S I D E N T , G E N E R A L C O U N S E L A N D S E C R E T A R Y


Key Responsibility: Oversee all laboratory operations

Previous Employment: vice president, division manager, integrated oncology and genetics, ARUP Laboratories

Education: MBA, Westminster College; BS, Kansas State University

Industry Organizations: past president, Utah chapter, Clinical Laboratory Management Association (CLMA); National CLMA; Association of Molecular Pathology (AMP); American Society of Clinical Laboratory Science (ASCLS)

At Exact Sciences, I’m working with an incredible team of dedicated industry leaders and laboratory professionals. I’m proud that we’ve created a nationally accredited clinical laboratory to offer all the services related to Cologuard, from processing to customer service.

ANA H O O K E RV I C E P R E S I D E N T , C L I N I C A L L A B O R A T O R Y O P E R A T I O N S

8


Key Responsibility: Oversee accounting, financial analysis, treasury and billing

Previous Employment: president of IT infrastructure outsourcing, Telephone & Data Systems, Inc (TDS); chief financial officer, telcom subsidiary, TDS; director, PriceWaterhouseCoopers, LLP

Education: MBA, Cornell University; BA, University of Wisconsin-Madison

Industry Organizations: Chartered Financial Analyst

Exact Sciences is a fantastically fast-paced company on a noble mission. While the company is focused on its first mission—helping eradicate colorectal cancer—it is also working very hard to develop additional products to help eliminate other cancers.

BILL M E G A NS E N I O R V I C E P R E S I D E N T , F I N A N C E


Key Responsibility: Oversee talent acquisition, organizational design, employee relations, development and engagement

Previous Employment: human resources manager, GE Healthcare; manager and project director, University of Wisconsin Survey Center

Education: MBA, BS, University of Wisconsin-Madison

Industry Organizations: Society for Human Resource Management (SHRM)

Exact Sciences’ people take great pride in their work and are dedicated to a common mission that we are driving toward together. I see a genuine commitment to the success of the team—not just the success of individuals. Our people are authentic, focused and share a common purpose: we are all playing a role in eradicating colon cancer.

SARAH C O N D E L L AV I C E P R E S I D E N T , H U M A N R E S O U R C E S

10


Key Responsibility: Lead the customer-facing sales team, training and operations

Previous Employment: vice president, sales, Novartis Vaccines; director, head of operations, senior product manager, head of sales training, GlaxoSmithKline Vaccines

Education: BS (Honors), University of Edinburgh, Scotland

There are two key aspects of Exact Sciences that excite me. The culture has attracted a team of knowledgeable, innovative and driven people who are passionate about what they do to ensure Cologuard’s success. And the innovation here not only impacts how colon cancer is screened and diagnosed but also has led to a robust pipeline of future diagnostics for other cancers.

DIANE R O G E R SV I C E P R E S I D E N T , S A L E S


Key Responsibility: Build focused clinical messages and publications demonstrating the medical value of Cologuard

Previous Employment: medical director, Quest Diagnostics Nichols Institute, Valencia CA; chief medical officer, bioTheranostics (bioMérieux); chief medical officer, Roche Molecular Diagnostics; vice president, pathology services, Genzyme Genetics (now LabCorp); vice president, laboratory director, Specialty Laboratories (now Quest); chief of pathology and laboratories, UCLA Santa Monica Hospital

Education: MD, University of Arizona College of Medicine; BS, University of Notre Dame

Industry Organizations: College of American Pathologists (CAP): Section Editor (Clinical Efficacy and Economics), CAP Archives of Pathology and Laboratory Medicine; CAP Economic Affairs Committee; CAP House of Delegates

I have a fantastic personal opportunity to lead the medical affairs team for a growing company with a novel product, Cologuard. As a result, I enjoy bringing physicians up to speed on the medical value of Cologuard. We also have a fantastic corporate opportunity to expand our efforts globally to help prevent colon cancer and other major cancers outside the United States.

MICHAEL D U G A NS E N I O R V I C E P R E S I D E N T , C L I N I C A L D E V E L O P M E N T A N D M E D I C A L A F F A I R S

12


Key Responsibility: Build relationships with key strategic academic, research, clinical, political, medical, professional and patient advocacy groups

Previous Employment: managed care executive; chair, Department of Pathology and Laboratory Medicine, Harvard Pilgrim Healthcare; faculty, Harvard Medical School

Education: Postdoctoral Fellow, Immunology/Oncology, University of Pennsylvania School of Medicine; MD, University of Pennsylvania School of Medicine; BS, University of Miami

It really does take a team and a lot of patience to move a mountain. But colorectal cancer is a preventable disease, and I’m proud of contributing to significantly changing the face of health care for an at-risk population.

BARRY B E R G E RC H I E F M E D I C A L O F F I C E R , M E D I C A L A F F A I R S


Key Responsibility: Develop and execute comprehensive regulatory and clinical strategies; maintain regulatory compliance for all commercialized products

Previous Employment: director/associate director, clinical operations, Quintiles; director, clinical affairs, Third Wave Technologies

Education: MS, BS, University of Wisconsin-Madison

Industry Organizations: Association of Clinical Research Professionals (ACRP); Drug Information Association (DIA); Regulatory Affairs Professionals Society (RAPS)

I am proud to have helped deliver the 10-0 vote in favor of Cologuard at the FDA Advisory Panel, followed closely by the FDA approval of Cologuard. The panel vote and subsequent approval are great examples of how team efforts at Exact Sciences lead to outstanding accomplishments.

SANDRA S T A T ZV I C E P R E S I D E N T , C L I N I C A L , Q U A L I T Y A N D R E G U L A T O R Y

14


Key Responsibility: Align information technology services with the priorities of the business

Previous Employment: co-founder and president, Performance G2, Inc.; executive vice president, Eclipse Networks, Inc; founder and president, Systems Solutions Group, Inc.

Education: MBA, Haas School; University of California, Berkeley; BS and BBA, University of Wisconsin-Madison

Industry Organizations: IBM Business Intelligence Partners Advisory Board, 2010-2011; Chair of Northern California Cognos User Group, 2004-2006

It is energizing and very motivating to help eradicate a disease like colorectal cancer. Leveraging data in sophisticated ways to make better business decisions is at the core of any successful company today. Being able to work every day with outstanding people on such a compelling health issue is extremely rewarding.

GARY F R I N G SC H I E F I N F O R M A T I O N O F F I C E R


Key Responsibility: Develop new products from feasibility through product launch, conduct performance studies for FDA submissions and support existing product lines

Previous Employment: vice president of product development, Eppendorf 5 Prime; director of product development, Hologic (formally Third Wave Technologies)

Education: PhD, University of Wisconsin, Milwaukee; BA, University of Wisconsin-Parkside

At Exact Sciences, I have the opportunity to do the work that I enjoy most: being able to assess, optimize and adapt new technologies. Creating cutting-edge diagnostic products that can improve or save lives is very rewarding.

MIKE D O M A N I C OV I C E P R E S I D E N T , P R O D U C T D E V E L O P M E N T

16


Key Responsibility: Oversee the production of reagent kits and collection kits utilized to conduct colon cancer screening tests

Previous Employment: site leader, Thermo Fisher Scientific; director, operations, Thermo Fisher Scientific (formerly Life Technologies and Invitrogen)

Education: PhD, University of Minnesota-Twin Cities; BS, University of Wisconsin-Madison

Industry Organizations: Society of Laboratory Automation and Screening; Executive Sponsor of iWIN (International Women’s Influential Network)

At Exact Sciences, I work every day with an extremely talented team of employees who are all focused on delivering world-class service to our customers. We are making a real difference in people’s lives through the early diagnosis and prevention of colon cancer.

TAMMY T U R E K - E T I E N N EV I C E P R E S I D E N T , O P E R A T I O N S


Key Responsibility: Lead the research and development systems department, developing the instrumentation and software used with Cologuard and future Exact Sciences’ products

Previous Employment: senior staff scientist, Gen-Probe, Inc.; director, product development, Nanogen, Inc.

Education: PhD, Columbia University; BS, Miami University

Exact Sciences has the right mix of people, technology and challenging work. Every day is a great day when you are making products that help beat cancer.

JAMES L I G H TV I C E P R E S I D E N T , S Y S T E M S D E V E L O P M E N T

18


Key Responsibility: Lead strategic planning and business development initiatives

Previous Employment: vice president of strategy, portfolio management & business development, early technologies/surgical division, Covidien (now Medtronic)

Education: MBA, Loyola University; BA, University of Northern Iowa

Health care needs to move from reactive to proactive care, and we have a long way to go. Very few companies in health care are disrupting diseases on as many levels as Exact Sciences. The model created here will be copied in many ways, for many years to come.

MICHAEL M I N E T T EV I C E P R E S I D E N T , B U S I N E S S D E V E L O P M E N T & S T R A T E G Y


Key Responsibility: Launch Cologuard in Europe and the Middle East

Previous Employment: vice president, Europe, Cytyc/Hologic

Education: Epsom College, London

I joined Exact Sciences to drive the implementation of new and innovative cancer screening products. We are changing current medical practice and saving lives. I see only stellar growth in our future.

WAYNE T A Y L O RV I C E P R E S I D E N T A N D H E A D O F E U R O P E A N D M I D D L E E A S T

20


Key Responsibility: Commercialize Cologuard and Exact Sciences’ pipeline products in Asia Pacific

Previous Employment: chief executive officer and president, Wafergen BioSystems; senior vice president genomics, Third Wave Technologies; vice president research operations, Pharmacia; director, new products oncology, Johnson & Johnson

Education: PhD, University of California, Los Angeles; MBA, Wharton School, University of Pennsylvania; BA, Hampton University

There are a lot of reasons I came to Exact Sciences: I get to work with a world-class management team that I already know well. I get to work in a can-do environment. And I get to help fight cancer and provide life-saving solutions for patients worldwide.

IVAN T R I F U N O V I C HV I C E P R E S I D E N T A N D H E A D O F A S I A P A C I F I C

KEY A C C O M P L I S H M E N T S

• Publication of DeeP-C clinical trial results in the New England Journal of Medicine

• Approval of Cologuard by the US Food and Drug Administration

• Coverage and payment decisions by the Centers for Medicare and Medicaid Services

• The early launch of Cologuard and its strong launch trajectory

• Product development partnerships with Mayo Clinic and The University of Texas MD Anderson Cancer Center

22

2015 P R I O R I T I E S

• Continuing to grow the Cologuard business

• Providing world-class service to physicians and patients through our customer care center

• Continuing to advance a valuable, clinically important pipeline of products

EXACT SCIENCES CORPORATION441 Charmany Drive, Madison, WI 53719 www.ExactSciences.com | www.ExactLabs.com

1-844-870-8870

Cologuard is a registered trademark of Exact Sciences Corporation.©2015 Exact Sciences Corporation. All rights reserved. ES24429-0615

exact sciences #exasirday: our leaders

Investor Relations

t h e e x

d e r s

n d p r e s i d e n

n o f t h e b o

kevin c o n r o y c

early detection of cancer

deadliest cancer

real difference